The E2F4 Knockout AGS Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population designed to disrupt the E2F4 gene in the AGS human gastric adenocarcinoma epithelial cell line. This loss-of-function model provides a robust tool for dissecting the transcriptional regulatory mechanisms governed by E2F4, a key repressor within the cell cycle machinery, without relying on monoclonal isolation or defined editing patterns. By targeting E2F4, researchers can explore its impact on gastric cancer cell behavior, leveraging a polyclonal pool to capture heterogeneous functional consequences relevant to tumor biology.
Derived from a female patient with gastric adenocarcinoma, the AGS cell line serves as a widely employed model for gastric cancer research, retaining epithelial characteristics essential for studying oncogenic signaling and therapeutic responsiveness. Its well-documented growth properties and sensitivity to pathway perturbations make it an ideal host for investigating the functional roles of cell cycle regulators. The knockout of E2F4 in this background offers a direct means to examine how loss of repressive control influences malignant phenotypes in a clinically pertinent setting.
E2F4 functions as a transcriptional repressor that, in complex with pocket proteins RB1, RBL1, and RBL2, inhibits the expression of E2F target genes to maintain quiescence and regulate the G0/G1 transition. Its activity is modulated by upstream signals including cyclin-dependent kinases CDK4/6, TGFB1, and p53, while it interacts with cofactors such as TFDP1, TFDP2, HDAC1, and SMAD3. Disruption of E2F4 releases repression on key downstream targets like CCNA2, CCNE1, CDK1, MYBL2, CDC25A, and TK1, thereby promoting cell cycle progression. This knockout model allows interrogation of the RB pathway and the interplay between E2F4 and its regulatory network, providing insights into how pocket protein?CE2F interactions control proliferation and arrest in epithelial cancer cells.
The loss of E2F4 in AGS cells likely enhances proliferative capacity and alters cell cycle dynamics, given its role as a gatekeeper of quiescence. This model is particularly valuable for studying gastric cancer pathogenesis, where aberrant cell cycle control is a hallmark. By removing the repressive influence of E2F4, the polyclonal knockout pool enables investigation into how gastric adenocarcinoma cells rewire survival and growth signaling, potentially revealing vulnerabilities exploitable for therapeutic intervention, especially in the context of CDK inhibitor sensitivity.
Researchers can apply this knockout model in a wide array of functional assays, including cell proliferation measurements via MTT or BrdU incorporation, cell cycle analysis by flow cytometry, and colony formation assays to evaluate tumorigenic potential. Further applications encompass western blotting for cell cycle proteins (e.g., cyclins, CDKs, RB), RT-qPCR profiling of E2F target genes, and migration/invasion studies using wound healing or transwell systems. The cells are also suitable for drug screening campaigns with CDK inhibitors such as palbociclib. For further details, please contact Ascent Research.
